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Introduction 
The World Health Organization (WHO) central nervous system tumor classification represents the primary 
source of updates on diagnostic classes, grades and criteria [17]. However, recent and ongoing advances in 
our understanding of brain tumor molecular pathogenesis warrant more rapid integration of this information 
into clinical practice between WHO updates. To accomplish this, cIMPACT-NOW (the Consortium to 
Inform Molecular and Practical Approaches to CNS Tumor Taxonomy) was established in 2016 [15, 16]. 
Since then, cIMPACT-NOW has convened three separate working committees to address classification and 
grading questions and challenges. Working Committee 1 focused on a concern that the classification and 
grading of Isocitrate Dehydrogenase (IDH)-wildtype diffuse astrocytic gliomas does not reflect our current 
understanding of the clinical outcomes associated with these tumors. 
 
Numerous high profile publications have documented the distinct genetic alterations and clinical behavior 
of IDH-mutant and IDH-wildtype diffuse astrocytic gliomas in the adult population[4, 6, 8]. Based on this, 
the WHO has designated IDH-mutant and IDH-wildtype diffuse astrocytic gliomas as distinct diagnostic 
categories within the 2016 update of the 4th edition [17, 19]. The WHO also recognizes H3 K27-mutant 
diffuse midline glioma as a tumor with aggressive clinical behavior corresponding to WHO grade IV[19]. 
Similarly, detection of an H3 G34 mutation in a diffuse glioma, irrespective of histological grade, indicates 
high grade biology with only modestly longer survivals than other IDH-wildtype glioblastomas [13, 28]. 
The WHO 2016 does not currently provide a separate classification or grade for H3 G34-mutant diffuse 
glioma. While these H3 K27- and H3 G34-mutant diffuse gliomas that occcur predominantly in childhood 
and adolescence do not contain IDH mutations, they should not be lumped together with other IDH-
wildtype astrocytic gliomas since they have another disease-defining molecular alteration that is associated 
with an aggressive clinical course.  For the remaining IDH-wildtype category, the WHO recognizes diffuse 
astrocytoma, WHO grade II, and anaplastic astrocytoma, WHO grade III, as provisional entities, and 
glioblastoma, WHO grade IV. The current criteria for establishing these diagnoses and grades have been 
based on traditional morphologic findings, with mitotic activity and anaplastic nuclear features 
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distinguishing WHO grade III from WHO grade II, and with the addition of microvascular proliferation 
and/or necrosis defining WHO grade IV. Multiple studies have concluded that a substantial subset of IDH-
wildtype diffuse or anaplastic astrocytomas that occur in adults and would be considered as WHO grade II 
or III based on histologic criteria (no microvascular proliferation or necrosis) have an aggressive clinical 
course, with overall patient survival times equal to or only slightly longer than patients with IDH-wildtype 
glioblastoma, WHO grade IV [4, 8, 9, 32, 34]. Nevertheless, biologically more favorable glial and 
glioneuronal tumors, such as ganglioglioma, pilocytic astrocytoma, pleomorphic xanthoastrocytoma, 
pediatric low-grade diffuse gliomas, and others are also IDH-wildtype and sometimes enter into the 
differential diagnosis. As such, the lack of IDH mutation alone is thus insufficient for designating a glioma 
as WHO grade IV. The identification of molecular markers in diffuse astrocytic gliomas that predict a 
clinical course corresponding to WHO grade IV, regardless of histologic grade, would be welcomed.  
 
Recommended grading parameters: combined +7/-10 and/or EGFR amplification and/or TERT 
promoter mutation 
We evaluated the literature to determine whether there is sufficient evidence to define a minimal set of 
molecular genetic criteria that could reliably identify IDH-wildtype diffuse or anaplastic astrocytomas that 
would behave most aggressively, similarly to glioblastoma and thus with a clinical course corresponding 
to WHO grade IV. Among the  molecular features initially considered were: losses of chromosome 10 
(whole chromosome, 10p or 10q); gains of chromosome 7 (whole chromosome, 7p or 7q); TERT promoter 
mutations; EGFR amplification; homozygous deletion of CDKN2A/B; and large-scale, microarray-based 
DNA methylation profiling. To discuss these possible markers, cIMPACT-NOW assembled a group of 
experienced tumor neuropathologists and clinical neuro-oncologists as Working Committee 1, which held 
three teleconferences in an open manner similar to the discussions held at WHO consensus meetings.  
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Since clinical management could be substantially altered by the use of such markers for grading, we agreed 
to consider only those genetic events that were highly specific for aggressive clinical behavior of IDH-
wildtype diffuse astrocytic gliomas. We were cautious in our interpretation of the literature, since most 
large studies on the relationship between genetic alterations and clinical outcomes have relied on 
retrospective cohorts in which patients were treated differently depending on institution, era and histologic 
classification. Moreover, we were cautious in our endorsements of markers because we envisioned that 
some diagnoses would likely be rendered by general pathologists possibly less familiar with brain tumor 
pathology, brain tumor molecular diagnostics, and the role of integrated diagnoses in currrent brain tumor 
diagnosis. 
 
We reached consensus that the following were the minimal molecular criteria for positively identifying an 
IDH-wildtype diffuse astrocytic glioma that, despite appearing histologically as a WHO grade II or III 
neoplasm, would follow an aggressive clinical course more closely resembling that of an IDH-wildtype 
glioblastoma: 
1) Combined whole chromosome 7 gain and whole chromosome 10 loss (+7/-10) 
AND/OR  
2) EGFR amplification 
AND/OR  
2) 3) TERT promoter mutation. 
These conclusions are based on the findings that those histologic IDH-wildtype diffuse astrocytic gliomas 
of WHO grade II or III that carry +7/-10, and/or EGFR amplification or TERT promoter mutation, are 
associated with significantly shorter patient survival compared to patients with other WHO grade II or III 
gliomas, and these patients have outcomes similar to patients with IDH-wildtype glioblastoma [1, 2, 11, 26, 
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27, 32, 33]. The large majority of IDH-wildtype diffuse astrocytic gliomas of WHO grade II or III with 
these genetic signatures correspond histologically to anaplastic astrocytoma, WHO grade III. For example, 
in the TCGA dataset of over 500 WHO grade II or III diffuse gliomas, there were only six IDH-wildtype 
diffuse astrocytomas, WHO grade II that had  +7/-10, and/or EGFR amplification or TERT promoter 
mutation [6]. In this small subset, clinical outcomes were similar to IDH-wildtype glioblastoma [6]. EGFR 
amplification has excellent specificity for gliomas with aggressive behavior, and is not present in other 
glioma subtypes that display a more indolent clinical course [27]. Of note, EGFR amplification refers to 
focal high-level copy number gains of the EGFR gene, as defined by validated techniques in clinical use. 
Low-level EGFR copy number gains,  e.g. trisomy 7, are not sufficient to qualify a tumor as EGFR-
amplified. Immunohistochemisty for EGFR protein does not provide adequate specificity for detecting 
EGFR amplification and should not be used to direct clinical care in this setting [14].  
 
The +7/-10 signature also has excellent specificity, with the rare exception of PXAs, where additional 
testing (e.g. BRAF V600E)  may be warranted in diagnostically challening cases [27].  Some studies have 
reported on gains of 7p or 7q, as well as losses of 10p or 10q as chromosomal imbalances linked to poor 
survival for patients with WHO grade II or III IDH-wildtype astrocytic gliomas [2, 27, 29, 32, 33].  
However, most studies reported whole gains of chromosome 7 and whole losses of chromosome 10 (+7/-
10), and the prognostic association of other, far less common imbalances, such as +7q/-10q, +7/-10q or 
+7q/-10, was not evaluated separately from +7/-10. A recent investigation by Stichel et al demonstrated 
that the signatures of +7q/-10 and +7/-10q were each present in approximately 10% of histologic grade 
II/III IDH-wildtype diffuse astrocytic gliomas and were associated with an adverse prognosis similar to the 
+7/-10 signature.  The +7q/-10 and +7/-10q signatures also demonstrated high specificity for aggressive 
behavior among IDH-wildtype astrocytic gliomas in that study[27]. Due to the small size of the +7q/-10 
(n=12) and +7/-10q (n=9) cohorts and the need for validation, the working group decided to restrict their 
recommendations primarily to the most common chromosomal imbalances in IDH-wildtype glioblastoma, 
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i.e. +7/-10, as an indicator of WHO grade IV behavior in  IDH-wildtype diffuse or anaplastic 
astrocytomas. 
 
TERT promoter mutations  
Other possible grading parameters 
TERT promoter mutations and CDKN2A/B homozygous deletions were also considered, since both are 
frequently present in IDH-wildtype glioblastoma and aggressively behaving WHO grade II or III astrocytic 
gliomas. However, these markers were felt to lack the high degree of specificity of +7/-10 and EGFR 
amplification.  TERT promoter mutationsThey occur most commonly with high frequency in IDH-wildtype 
gliomas with +7/-10 and/or EGFR amplification, yet these markers do not have complete overlap. When 
present in IDH-wildtype WHO grade II or III diffuse astrocytic gliomas, TERT promoter mutations are 
associated with aggressive clinical behavior, even in some cases without +7/-10 and/or EGFR amplification 
[2, 8, 32, 33].  Therefore, if the clinical, radiologic and histopathologic features are definitive for of a 
diffusely infiltrative astrocytic glioma, TERT promoter mutations appear tocan be considered as a marker 
for be associated with WHO grade IV behavior. However, it should be emphasized that other types of IDH-
wildtype glial neoplasms without WHO grade IV histology or aggressive clinical behavior have also been 
reported to occasionally harbor TERT promoter mutations, including tumors classified as pleomorphic 
xanthoastrocytoma, ganglioglioma, anaplastic glioma with piloid features, and ependymoma [12, 25, 27, 
31]. Although some of these entities could be distinguished from a diffuse astocytic glioma based on 
morphology, others could pose a challenge, especially in a small biopsy. Therefore, by itself, TERTit is 
critcally important to establish that a CNS neoplasm is diffusely infiltrative before applying TERT promoter 
mutation as s did not meet our strict criteria as a specific, independent marker of WHO grade IV behavior 
in IDH-wildtype gliomas, but it remains a potentially compelling marker of aggressive behavior. Further 
In this regard, further study ofTh combination of TERT promoter mutations in combination mutation with 
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other markers, such as EGFR amplification and, +7/-10 adds specificity as a marker of grade IV behavioror 
CDKN2A deletion, or in the context of larger data sets, are warranted and could lead to inclusion in future 
grading criteria [27]. The finding of prognostic interaction of TERT promoter mutations with MGMT 
promoter methylation in patients with IDH-wildtype glioblastoma treated with radiochemotherapy with 
temozolomide provides additional rationalization for warrants futher study [3, 21]. 
 
 
Other possible grading parameters 
 
Homozyous CDKN2A/B deletions also occur with high frequency in aggressively behaving IDH-wildtype 
diffuse astrocytic gliomas with +7/-10, and/or EGFR amplification, or TERT promoter mutations that show 
aggressive clinical behavior. However, other types of glioma also harbor CDKN2A/B deletions, but do not 
have histologic properties, genetic findings or clinical behavior associated with canonical IDH-wildtype 
glioblastoma. For example, pleomorphic xanthoastrocytomas often harbor a combination of BRAF 
mutations and CDKN2A/B deletions but are associated with substantially better clinical outcomes than IDH-
wildtype glioblastoma [30]. Another subset of IDH-wildtype astrocytic gliomas has recently been 
delineated as anaplastic astrocytoma with piloid features, characterized by frequent CDKN2A/B deletions 
and typically accompanied by BRAF pathway gene alterations and ATRX mutation or loss of nuclear 
expression. The respective patients have a more favorable clinical outcome than patients with IDH-wildtype 
glioblastoma[25]. Therefore, by itself, CDKN2A/B deletion is not sufficient as a marker for WHO grade IV 
behavior in an IDH-wildtype astrocytic glioma. 
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Whole genome DNA methylation profiling represents a robust and reproducible method for precisely 
segregating tumor types that have similar histogenesis, genetic signatures and clinical behaviors [5, 6]. 
IDH-wildtype diffuse astrocytic gliomas of WHO grade II or III with genetic features suggesting aggressive 
clinical behavior (+7/-10, EGFR amplification, TERT promoter mutation) have been shown to cluster 
tightly with IDH-wildtype glioblastoma based on DNA methylation profiling [6, 10, 26]. Other forms of 
gliomas with indolent clinical features do not cluster together with these tumors, indicating a high degree 
of specificity for this signature[5]. While the literature indicates this method is superior for classification 
purposes and could have a role in grading, it currently lacks widespread clinical implementation due to 
regulatory challenges and prevailing practice patterns that test primarily for mutations and copy number 
alterations, as well as a reluctance due to uncertainties in reimbursement. Where available, DNA 
methylation profiling may be an attractive alternative for identifying IDH-wildtype diffuse astrocytic 
gliomas histologically corresponding to WHO grade II or III that have molecular profiles and clinical 
behavior of IDH-wildtype glioblastoma, WHO grade IV. 
 
The most recent WHO classification stresses the importance of an integrated diagnosis that incorporates 
histologic classification, molecular genetic findings and WHO grade[17-19].  Because much of the data 
discussed above was not mature in 2014 and 2015, the Haarlem and WHO meetings concluded that grading 
be based on histological parameters for the 2016 WHO update[17-19]. The current data, however, show a 
clear disconnect between histological appearance and clinical behavior; histologically defined WHO grade 
II or III IDH-wildtype diffuse or anaplastic astrocytomas with +7/-10, and/or EGFR amplification or TERT 
promoter mutation behave clinically as WHO grade IV neoplasms. Since grade is intended to predict 
clinical behavior, an integrated histological and molecular grade (see Table 1) should take precedence over 
a strictly histological grade in this instance.  In addition, histologic features can be spatially variable within 
a given tumor, resulting in the potential for undersampling and leading to a histologic diagnosis that 
underrepresents a tumor’s malignant potential. The key genomic alterations described above, on the other 
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hand, appear to be more spatially uniform, potentially resulting in a lower likelihood of molecular 
undersampling, even when the tissue sample is small.  
 
Diffuse astrocytic glioma, IDH-wildtype with molecular features of glioblastoma, WHO grade IV 
With regard to the most appropriate classification, based on genetic similarity and comparable clinical 
course, it could be argued that these tumors are most appropriately classified as glioblastoma, IDH-
wildtype, despite not meeting the formal histological criteria. However, there has been reluctance to 
designate a tumor as a glioblastoma in the absence of histological features of glioblastoma and major 
changes in brain tumor classes and ICD-O codes are best considered as part of the official WHO 
classfication [20]. We therefore reached consensus on the designation diffuse astrocytic glioma, IDH-
wildtype, with molecular features of glioblastoma, WHO grade IV as the most appropriate terminology at 
this time, since this conveys the histologic, molecular and clinical features of glioblastoma, but does not 
alter the long-standing histologic definition. Nonetheless, it is expected that diagnoses will be rendered in 
a layered format since, by doing so, a diagnosis can clearly show all of the histological and molecular 
features of any particular lesion (see Table 1). 
 
The diagnosis of diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, together 
with the designation of integrated WHO grade IV based on molecular parameters, has inherent clinical 
implications. It will support the current practice of recommending combined chemo- and radiotherapy to 
patients with IDH-wildtype anaplastic astrocytoma and, potentially, IDH-wildtype diffuse astrocytoma if 
these have +7/-10, and/or EGFR amplification or TERT promoter mutation. For clinical trials, these changes 
will extend inclusion criteria to allow such patients access to innovative treatments based on their individual 
risk profile rather than histological diagnosis alone. These clinical trials will ultimately also allow validation 
of our recommendations in prospective datasets. 
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 Caveats 
Importantly, not all IDH-wildtype diffuse or anaplastic astrocytomas have genetic features or clinical 
outcomes similar to IDH-wildtype glioblastoma, in particular those tumors that occur in younger patients, 
which is notable for classification and appropriate clinical management. These small subsets lack the 
prototypic genetic alterations of IDH-wildtype glioblastoma, such as +7/-10, EGFR amplification, TERT 
promoter, PTEN, or TP53 mutations, or CDKN2A/B homozygous deletions. One group has distinct 
methylation and gene expression profiles and harbors activating BRAF V600E mutations, but few other 
concurrent mutations and copy number alterations [6, 7]. Additional studies are needed on clinical 
outcomes, yet these patients appear to have a favorable prognosis and some may be responsive to targeted 
therapies. Also deserving of further study are a small group of IDH-wildtype diffuse astrocytic gliomas that 
harbor MYB/MYBL alterations [1, 24]. Tumors with this single driver genetic alteration occur predominantly 
in childhood, but have also been described in adults, and have a more indolent clinical course. Thus, the 
lack of IDH mutation in a diffuse astrocytic glioma, including the examples provided here, does not always 
equate with aggressive clinical behavior, highlighting the importance of documenting additional disease-
defining genetic events to guide clinical care. 
 
In addition, most studies that relate genetic signatures to clinical outcomes for IDH-wildtype diffuse 
astrocytic gliomas have been performed on tumors arising in the supratentorial compartment of adults.  
Signatures predictive of aggressive clinical behavior will not apply to most pediatric diffuse gliomas and 
may not be relevant to diffuse gliomas arising in other less common sites.  For example, IDH-wildtype 
diffuse astrocytic gliomas that arise in the cerebellum of adults are rare, and recent studies indicate that they 
do not harbor the same percentage of EGFR amplification, TERT promoter mutations, and alterations of 
chromosomes 7 and 10 as their supratentorial counterparts[22, 23]. A subset will harbor H3 K27 or SETD2 
mutations, but the full spectrum of their other alterations have not been defined, nor have the genetic events 
corresponding to aggressive behavior. Thus, the genetic signature that predicts poor clinical outcomes for 
histologic grade II/III IDH-wildtype diffuse astrocytic gliomas of the cerebellum may not similar to those 
of supratentorial tumors.   
 
Summary  
Working Committee 1 concluded that histologic grade II and III IDH-wildtype diffuse astrocytic gliomas 
that contain high-level EGFR amplification and/or the combination of whole chromosome 7 gain and whole 
chromosome 10 loss (+7/-10), and/or TERT promoter mutations,  correspond to WHO grade IV and should 
be referred to as diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO 
grade IV. Assessment of TERT promoter mutation, classification by DNA methylation profiling, and 
additional +7/-10 signatures appear to bere promising as well and markers , warrant further study and could 
be considered in the future following additional experience and validation. We also concluded that specific 
molecular signatures in subsets of IDH-wildtype diffuse astrocytic gliomas are associated with better 
clinical outcomes and should not lead to a high-grade designation, including, but not limited to, those 
gliomas with MYB/MYBL or BRAF alterations as individual drivers. 
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Table 1 
Sample layered diagnosis and integrated grade for Diffuse astrocytic glioma, IDH-wildtype with 
molecular features of glioblastoma, WHO grade IV. 
 
Integrated diagnosis: Diffuse astrocytic glioma, IDH-wildtype with molecular features of 
glioblastoma, WHO grade IV. 
Histological diagnosis: Anaplastic astrocytoma 
Molecular information: 
 IDH: wildtype (IDH1 and IDH2, sequencing) 
 EGFR: High-level amplification (FISH) 
 Chromosome 7/10 status: whole chromosome 7 gain/ whole chromosome 10 loss (FISH) 
 TERT promoter: mutated (sequencing) 
Integrated histologic and molecular grade: WHO grade IV  
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